Home Visit
Upload
AFB Drug Susceptibility Panel Additional Drugs 4 Nos. MACC By MGIT - Pure Culture
Also known as: AFB Drug Susceptibility Panel - (4 drugs) MACC, Pure Culture
No special precautions
Sample Type
Blood
Recommended for
Male, Female
Report
Within 24 Hours
Blood test at Home
NABL & CAP Accredited Labs
Accurate & Quality Test Reports
Trusted by Leading Doctors & Hospitals
AFB DST Panel Overview
The "AFB Drug susceptibility - Additional drugs 4 Nos. MACC panel by MGIT - Pure Culture" test is a critical diagnostic tool used for tuberculosis (TB) treatment. This test utilizes the MGIT (Mycobacteria Growth Indicator Tube) method on pure cultures of Mycobacterium tuberculosis (MTB) Complex to assess the drug susceptibility of MTB to four additional anti-tuberculosis drugs: Moxifloxacin, Amikacin, Clofazimine, and Capreomycin, collectively known as the MACC panel. The clinical utility of this test lies in its ability to provide essential information to healthcare professionals about the effectiveness of these additional drugs against the MTB Complex causing TB. By evaluating drug susceptibility to these four drugs in combination with other first-line and second-line drugs, this test helps in the management of complex and drug-resistant TB cases. The results enable clinicians to tailor personalized and effective treatment regimens, ensuring optimal care and increasing the chances of successful TB treatment. Overall, the AFB Drug susceptibility - Additional drugs 4 Nos. MACC panel by MGIT plays a crucial role in tuberculosis treatment, providing a comprehensive understanding of drug susceptibility patterns to guide targeted therapy. By enabling the selection of appropriate and effective drug combinations, this test significantly contributes to improved patient outcomes, better management of drug-resistant TB cases, and the overall fight against tuberculosis.
The AFB DST Panel Additional Drugs 4 Nos. MACC By MGIT - Pure Culture is a crucial diagnostic test used to evaluate the susceptibility of Mycobacterium tuberculosis (MTB) to four additional anti-tuberculosis drugs: moxifloxacin, amikacin, clofazimine, and capreomycin (MACC). This test employs the Mycobacteria Growth Indicator Tube (MGIT) method on pure cultures of MTB Complex to determine the effectiveness of these drugs against the bacteria causing tuberculosis (TB).
The AFB DST Panel plays a vital role in managing complex and drug-resistant TB cases by identifying whether the MTB strain is resistant to first-line and second-line anti-TB drugs. The results of the AFB DST Panel enable doctors to tailor personalised and effective treatment regimens for TB patients, ensuring optimal care and increasing the chances of successful treatment outcomes.
Reasons for Undergoing the AFB DST Panel
There are several important reasons for undergoing the AFB DST Panel:
- To identify resistance to first-line and second-line anti-TB drugs, facilitating the management of complex and drug-resistant TB cases.
- To provide essential information for doctors to develop personalised and effective treatment plans for TB patients.
- To evaluate drug susceptibility to additional drugs and improve the chances of successful TB treatment.
- To provide a comprehensive understanding of drug susceptibility patterns.
List of Parameters Considered During the AFB DST Panel
The AFB DST Panel measures the susceptibility of MTB to the following four drugs:
- Moxifloxacin: A fluoroquinolone antibiotic used as a second-line drug for TB treatment.
- Amikacin: An aminoglycoside antibiotic used as a second-line drug for TB treatment.
- Clofazimine: A riminophenazine antibiotic primarily used for leprosy treatment but also as a second-line drug for TB.
- Capreomycin: A polypeptide antibiotic used as a second-line drug for TB treatment.
These measurements indicate whether the MTB strain is susceptible or resistant to each drug, providing critical information for formulating effective treatment regimens, especially in cases of drug-resistant TB.
AFB DST Panel Preparation
Preparing for the AFB DST Panel involves several steps:
- Sample Collection: A sputum or other clinical sample is collected from the patient suspected of having TB.
- Culturing: The collected sample is cultured to isolate and grow MTB complex in a pure culture, ensuring the accuracy of the susceptibility testing.
- MGIT Method: The Mycobacteria Growth Indicator Tube (MGIT) method is employed to assess the growth of MTB in the presence of the four additional drugs (MACC).
- Laboratory Processing: The samples are processed in a laboratory setting using the MGIT system, following strict protocols to ensure reliable results.
- No Special Preparations Required: Generally, no special preparations, such as fasting, are required from the patient, as this is a culture-based test rather than a blood-based test.
AFB DST Panel Results & Interpretation
The results of the AFB DST Panel indicate whether the MTB strain is susceptible or resistant to each of the four tested drugs:
- Susceptible: If the MTB strain does not grow in the presence of a particular drug, it is considered susceptible to that drug.
- Resistant: If the MTB strain grows in the presence of a particular drug, it is considered resistant to that drug.
- Interpretation: The results help clinicians select appropriate and effective drug combinations for treating TB, particularly in cases of drug-resistant TB. This personalised approach ensures optimal care and increases the chances of successful TB treatment.
Home Collection for AFB DST Panel
Metropolis Healthcare offers a convenient home sample collection service for the AFB DST Panel Additional Drugs 4 Nos. MACC By MGIT - Pure Culture. A trained phlebotomist will visit your home to collect the necessary samples, ensuring comfort, safety, and adherence to high standards of sample handling. This service maintains testing accuracy while providing timely and reliable results. By making healthcare more accessible, Metropolis Healthcare demonstrates its commitment to delivering quality diagnostic solutions conveniently at home, empowering patients to manage their health proactively.
AFB Drug Susceptibility Panel - (4 drugs) MACC, Pure Culture Price
Metropolis Healthcare is a leading diagnostics centre and pathology lab in India equipped with the latest state-of-the-art technologies that provides the AFB Drug Susceptibility Panel - (4 drugs) MACC, Pure Culture with a clear pricing structure.
The AFB Drug Susceptibility Panel - (4 drugs) MACC, Pure Culture Price in Mumbai is ₹ 5,935 .
We are committed to deliver accurate and quality results from the best labs in India with complete transparency regarding test cost and turnaround time. No matter where you are, we strive to offer patients high-quality service that is affordable and accessible.
Frequently Asked Questions
This test measures the susceptibility of Mtb, the bacterium that causes TB, to four specific drugs: Moxifloxacin, Amikacin, Clofazimine, and Capreomycin.
• To guide the treatment of TB
• To evaluate the effectiveness of current treatments
• To prevent the spread of drug-resistant TB strains
This test is recommended for individuals suspected or diagnosed with TB, especially if they have a high risk of drug resistance or treatment failure. It is useful for • assessing drug resistance in patients not responding to standard TB treatment, • evaluating patients with a history of TB treatment or contact with drug-resistant TB cases, and • monitoring and optimizing treatment plans for TB patients.
Abnormal results may suggest drug resistance, which can complicate treatment.
During this test, a healthcare professional will collect a sample of the Mycobacterium tuberculosis (Mtb) complex from your body. They will send the sample for analysis using the MGIT (Mycobacteria Growth Indicator Tube) method.
• Provide accurate clinical history and specimen type when submitting the sample.
• Your doctor may provide additional instructions depending on your specific situation. • Inform your doctor if you have any specific requirements.
• AFB Smear Test: This test detects the presence of Mtb bacteria in a patient's sputum or other body fluids.
• GeneXpert MTB/RIF Test: It identifies TB bacteria and also checks for resistance to Rifampicin, an important anti-TB drug.
AFB DST Panel or Mycobacterial Drug Susceptibility Testing
Tuberculosis (TB) is a contagious infection caused by the bacterium Mycobacterium tuberculosis. It primarily affects the lungs but can also target other organs. TB spreads through the air when an infected person coughs or sneezes, and it can be life-threatening if left untreated.
The AFB DST Panel is a diagnostic test that evaluates the susceptibility of Mycobacterium tuberculosis (MTB) to various anti-tuberculosis drugs. It identifies which medications the bacteria are resistant to, helping doctors select effective treatment regimens for patients with tuberculosis.
Home sample collection is available for the AFB DST Panel. A trained phlebotomist will visit your home to collect the blood sample, ensuring that the sample is handled with the highest standards of care and accuracy.
There are no "normal levels" for an AFB DST Panel. The results indicate whether the MTB strain is susceptible or resistant to the tested drugs.
The AFB DST Panel is used to determine the susceptibility of MTB to various anti-tuberculosis drugs. It aids in managing tuberculosis, especially drug-resistant cases, by guiding doctors in selecting effective treatment regimens.
The frequency of testing depends on the clinical context. This test is typically performed when a patient is diagnosed with tuberculosis, and there is a need to assess drug susceptibility.
There is no specific time of day recommended for the AFB DST Panel. Follow the advice of your doctor.
Fasting is not required for the AFB DST Panel. The test involves analysing a clinical sample (such as sputum, blood, or tissue).
Precautions include ensuring proper sample collection and handling to avoid contamination and maintain the integrity of the sample until it is processed in the laboratory. Follow any specific instructions provided by your doctor for optimal results.
The AFB DST Panel assesses the susceptibility of MTB to four additional anti-tuberculosis drugs: moxifloxacin, amikacin, clofazimine, and capreomycin (MACC). These measurements indicate whether the MTB strain is susceptible or resistant to each of these medications.
The AFB DST Panel should be performed when a patient is diagnosed with tuberculosis, and there is a need to evaluate drug susceptibility, especially if there are indications of drug resistance or if the patient is not responding to first-line treatments.
The AFB DST Panel typically takes around 30-45 minutes to complete, depending on the individual's responses and consistency.
The turnaround time for AFB DST Panel reports is typically within 4 weeks and varies depending on the lab and the complexity of the case. For the exact turnaround time, you can consult with your healthcare provider or the specific lab.
Ratings & Reviews (0)
Why Metropolis?
Metropolis has a team of 200 senior pathologists and over 2000 technicians delivering diagnostic solutions in the areas of routine, semi specialty and super specialty domains like Oncology, Neurology, Gynaecology, Nephrology and many more.
We offer a comprehensive range of 4000+ clinical laboratory tests and profiles, which are used for prediction, early detection, diagnostic screening, confirmation and/or monitoring of the disease.
WhatsApp